122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase 2 TrIuMPH trial assessing EBX-102-02 EnteroBiotix completed enrolment ahead of its planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback